These groups have further been used to investigate differences on the pathway activation level (Fig. 4B) using the iPANDA algorithm [41] A specific signaling pathway named “Regulation of PLK1 Activity at G2-M Transition” (R-HSA-2565942) was among the 5% of most significantly upregulated pathways in sarcoma patients with poor health outcome (Fig. 4B). This evidence concerns the gene PLK1 and sarcoma.